

PATIENT ONCOLOGY HISTORY

Age: 35-Year-Old Male

Diagnosis: Metastatic well-differentiated Neuroendocrine Tumor


Previous Treatments: The patient was receiving Ing. Sandostatin-LAR 30 monthly for the last six months with no relief from symptoms and progressing disease.

Clinical Assessment before treatment procedure: The patient has a history of abdominal pain for 6 months.

LUTETIUM PRRT THERAPY


The patient received a total of 3 doses of 177Lu PRRT administered via slow intravenous infusion with renal protection protocol (Hydration with intravenous normal saline). Each infusion was well-tolerated, and there were no immediate complications. The patient's clinical condition significantly improved, with no weight loss or loss of appetite. Overall energy levels have improved.

At each 3-month interval, subsequent doses of 177Lu PRRT were administered, patient continued to tolerate the treatment well without any post-infusion complications. Upon completion of the therapy, the patient was discharged in a stable condition with background radiation levels within normal limits.



Pre Therapy Chromogranin A level 353

Post 03 cycle of Lu-177 PRRT Therapy S. Chromogranin A level 132



Interim treatment response Ga-68 DOTANOC PET CT scan shows ~42% reduction in tumor volume with complex relief of symptoms and improvement in quality of life

Discuss your case with

Dr. Ishita B. Sen and get a second opinion



+91 98111 27080

Useful Links

- Case Study: Lutetium 177 PSMA Therapy as the first line of treatment for Metastatic Prostate Carcinoma
- Case Study: 177Lu DKFZ-PSMA-617 in Metastatic Prostate
- Metastasis directed Lu-177 PSMA Therapy in Prostate Cancer
- Patients with Oligometastatic Disease

Adenocarcinoma

How is PRRT Performed

How Does A Typical PRRT Day Look Like?